Cellectar Biosciences, Inc. Operating Lease, Expense
Cellectar Biosciences, Inc. (CLRB) reported Operating Lease, Expense of $113.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-21
- Cellectar Biosciences, Inc. operating lease, expense for the quarter ending 2021-03-31 was $28.00K, a 0.00% change year-over-year.
- Cellectar Biosciences, Inc. operating lease, expense for the quarter ending 2020-12-31 was $28.00K, a 0.00% change year-over-year.
- Cellectar Biosciences, Inc. operating lease, expense for the quarter ending 2020-09-30 was $0.00.
- Cellectar Biosciences, Inc. operating lease, expense for the quarter ending 2020-06-30 was $57.00K.
- Cellectar Biosciences, Inc. operating lease, expense for fiscal 2021 was $113.00K, a 0.00% change from fiscal 2020.
- Cellectar Biosciences, Inc. operating lease, expense for fiscal 2020 was $113.00K, a 0.00% change from fiscal 2019.
- Cellectar Biosciences, Inc. operating lease, expense for fiscal 2019 was $113.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $113.00K 10-K · filed 2022-03-21 | |||
| 2021-03-31 | $28.00K 10-Q · filed 2021-05-10 | $56.00K derived: sum of 2 quarters · filed 2021-05-10 | $56.00K derived: sum of 3 quarters · filed 2021-05-10 | $113.00K derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $28.00K derived: sum of 2 quarters · filed 2021-03-02 | $85.00K derived: sum of 3 quarters · filed 2021-03-02 | $113.00K 10-K · filed 2021-03-02 |
| 2020-09-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2021-03-02 | $57.00K derived: sum of 2 quarters · filed 2021-03-02 | $85.00K 10-Q · filed 2020-11-09 | $113.00K derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-06-30 | $57.00K 10-Q · filed 2020-08-10 | $85.00K derived: sum of 2 quarters · filed 2020-08-10 | $113.00K derived: sum of 3 quarters · filed 2020-08-10 | |
| 2020-03-31 | $28.00K 10-Q · filed 2020-05-07 | $56.00K derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $113.00K 10-K · filed 2020-03-09 | ||
| 2019-09-30 | $85.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |